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Background: The role of serum 25-hydroxyvitamin D (25 (OH) D) in atherogenesis is unclear. We investigated
whether the 25 (OH) D is independently associated with the carotid intima–media thickness (CIMT) and carotid
plaques in normotensive and euglycemic postmenopausal women.
Methods: A total of 671 normotensive and euglycemic postmenopausal women (mean age, 58.8 years) were
enrolled from the Changfeng Study. A standard interview, anthropometrics measurements and laboratory analyses
were performed for each participant. Bilateral CIMTs were measured using ultrasonography, and the presence of
carotid plaques was assessed. The serum 25 (OH) D was measured using electrochemiluminescence immunoassay.
Results: Serum 25 (OH) D was 43.6 ± 18.2 nmol/L in the postmenopausal women. Compared with subjects with 25
(OH) D in the first, second and third quartiles, subjects with 25 (OH) D in the fourth quartile had decreased CIMT
and prevalence of carotid plaque (0.684 ± 0.009 mm vs 0.719 ± 0.009 mm, 0.708 ± 0.009 mm and 0.709 ± 0.009 mm;
10.8% vs 19.0%, 14.8% and 16.8%, respectively). After adjusting for conventional CVD risk factors, PTH, liver and renal
function, postmenopausal women with 25 (OH) D in the fourth quartile still had lower CIMT than those in the first,
second and third quartiles (p = 0.039) and the subjects in the fourth quartile had a 0.421-fold decreased risk of
carotid plaques relative to those in the lowest quartile (95% confidence interval 0.209 to 0.848).
Conclusions: These results suggest serum 25 (OH) D is independently and inversely associated with carotid
atherosclerosis in postmenopausal women with normal blood pressure and normal glucose tolerance.
Keywords: 25-hydroxyvitamin D (25 (OH) D), Carotid intima-media thickness (CIMT), Carotid plaque, Carotid
atherosclerosisBackground
Vitamin D, a fat-soluble vitamin and steroid hormone, is
well known for its pivotal role in calcium homeostasis
and bone metabolism. Beyond the role in bone health,
vitamin D is receiving increasing attention for its influence
on non-skeletal health problems and chronic diseases
[1,2]. Serum 25-hydroxyvitamin D (25(OH) D), the major
storage form of vitamin D, is formed in the liver, and is a* Correspondence: zhongshan_endo@126.com
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unless otherwise stated.clinical indicator of overall vitamin D3 status [3]. The
association of serum 25 (OH) D levels with cardiovas-
cular diseases (CVD) is debated in the literature. The
Framingham Offspring Study revealed that low serum
25 (OH) D was independently associated with an increased
incidence of CVD in Caucasians during a 5.4-year
follow-up period [4]. Additionally, European studies
have shown that serum 25 (OH) D levels are inversely
associated with the prevalence of CVD and carotid
intima-medial thickening in patients with type 2 diabetes
mellitus (DM) [5]. More recently, the meta-analysis
by Wang et al. [6] of nineteen independent prospectives is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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serum 25 (OH) D concentrations and risk of CVD
outcome. However, several other studies observed no
significant association between serum 25 (OH) D
levels and CVD. For example, Deleskog A et al and
Blondon M et al demonstrated that levels of 25 (OH)
D showed multiple associations with established and
emerging cardiovascular risk factors but were not consist-
ently, independently related to measures of carotid IMT
and carotid plaque[7,8]. The Korean National Health and
Nutrition Examination Survey (KNHANES-2008-2009)
indicates that the prevalence of CVD is not associated
with low serum 25 (OH) D levels in the total population
[9]. The study by Melamed et al. [10], using the third
National Health and Nutrition Examination Survey
cohort, while CVD risk was not statistically significant,
the all-cause mortality data suggested a U- or reverse
J-shaped dose-relationship, with increased total mortality
for both the lowest and highest serum 25 (OH) D concen-
trations (<44.4 and >80.1 nmol/l, respectively) in this
cohort followed for 9 years. As noted, the majority of the
previous studies were conducted using populations with
different proportions of hypertension or diabetes. In
addition, 25 (OH) D is associated with hyperglycemia and
hypertension [11], which may themselves be linked to
CVD. Therefore, the association between 25 (OH) D and
atherosclerosis may be confounded by the inclusion of
subjects with hypertension, diabetes or pre-diabetes.
Moreover, it has been shown that 25 (OH) D values vary
between different ethnicities. There are few reports on the
relationship between 25 (OH) D and CVD in the Chinese
postmenopausal women. Given the high risk of CVD in
this population [12], more evidence is needed to evaluate
the association between 25 (OH) D and atherosclerosis in
the Chinese postmenopausal women.
The use of high-resolution color-coded duplex sonog-
raphy offers the opportunity to assess the carotid
intima-media thickness (CIMT) and carotid plaques
as reliable markers of atherosclerosis [13]. Therefore,
in the present study, we investigated the relationship
between 25 (OH) D and carotid atherosclerosis in a




The subjects were participants in the Changfeng Study,
a community-based study of chronic diseases among
middle-aged and elderly individuals which has been de-
scribed elsewhere [14]. The Changfeng community is a
middle-class community in Shanghai [14]. From June 2009
to June 2012, 2717 postmenopausal women were initially
enrolled. We excluded 2046 participants for the following
reasons: lack of physical examination and laboratoryassessments (n = 51), prevalent CVD (myocardial infarction,
stroke, or peripheral arterial disease) (n = 202), prevalent
hemodialysis (n = 2), bone fracture within 3 months
and use of drugs known to influence bone metabolism
including the use of postmenopausal hormone therapy,
calcium, diphosphonate, vitamin D and glucocorticoid
(n = 384), prevalent hypertension (systolic blood pres-
sure ≥ 140 mmHg, diastolic blood pressure ≥90 mmHg,
the use of antihypertensive medications, or diagnosed
hypertension) (n = 1076), prevalent diabetes mellitus
or pre-diabetes (fasting glucose ≥5.6 mmol/L, OGTT
2 h glucose ≥7.8 mmol/L, the use of hypoglycaemic
medications, or diagnosed diabetes; n = 320), or the
use of lipid-lowering therapy or use of the antiplatelet
agents (n = 11). Finally, 671 subjects were included in
the analysis.
The study was approved by the ethical committee of
Zhongshan Hospital, Fudan University and was conducted
in accordance with the guidelines of the Declaration
of Helsinki. All the patients provided consent upon
enrolment in the study. Interviews, physical examinations
and ultrasound scans were performed at the Changfeng
Community Health Service Center.
Clinical measurements
Letters were sent to participants with instructions asking
them not to alter their diet or level of physical activity
for at least 3 days before the test. A questionnaire was
administered by trained nurses to evaluate the medical
history and lifestyle of each participant. Weight and
height were measured while the participant was clothed in
a light gown. The body mass index (BMI) was calculated
as the weight divided by the height squared (kg/m2). The
waist circumference was measured midway between the
lowest rib margin and the iliac crest in a standing position,
and the hip circumference was measured at the widest
level over the greater trochanters. The waist-to-hip ratio
(WHR) was calculated as the waist circumference divided
by the hip circumference. The resting blood pressure was
measured three times, and the mean value was used for
the analysis. Blood samples were obtained after a fasting
period of at least 10 hours. Total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C), triglycerides
(TG) and liver enzymes were measured using a model
7600 automated bio-analyser (Hitachi, Tokyo, Japan). The
level of low-density lipoprotein cholesterol (LDL-C) was
calculated using the Friedewald equation. The fasting
blood glucose (FBG) and 2 h glucose levels following
a 75-g oral glucose challenge (PPG) for non-diabetics
were measured using the glucose oxidase method.
The glomerular filtration rate (GFR) was estimated
based on the serum creatinine concentration using
the Modification of Diet in Renal Disease (MDRD)
formula: estimated GFR (eGFR) = 186 × [serum creatinine
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The serum 25(OH)D, parathyroid hormone (PTH)
and insulin were measured by electrochemilumines-
cence immunoassay using an immunoassay analyzer
(Roche Cobas-6001, Switzerland; coefficient of vari-
ation <4.0%, <5.0% and <5.0%, respectively). Homeostasis
model assessment index for insulin resistance (HOMA-IR)
and beta cell function (HOMA-%B) were used to estimate
insulin sensitivity and insulin secretion [16].
The carotid arteries of the participants were evaluated
by an experienced radiologist who was blinded to the
participants’ details using a GE Logic P5 (GE Healthcare,
Milwaukee, USA) scanner with a 10-MHz probe. The
CIMTs on both sides were measured in the common
carotid artery approximately 1 cm proximal to the
bifurcation at the far wall during end diastole. The
CIMT was quantified at plaque-free sections of the carotid
arteries as the distance between the lumen–intima and
media–adventitia interfaces. Three values were measured
on each side, and the average CIMT values were used for
the analysis. The study procedure involved scanning the
near and far walls of both common carotid arteries,
the carotid bifurcation, and the internal carotid artery
for the presence of plaques, defined as the presence
of focal wall thickening resulting in a thickness that
is at least 50% greater than that of the surrounding
vessel wall or as a focal region with a CIMT greater
than 1.5 mm that protrudes into the lumen that is
distinct from the adjacent boundary, according to
American Society of Echocardiography [17]. Repeated
measurements on the same subjects (performed in
104 subjects) for CIMT and carotid plaque yielded an
intraclass correlation coefficient (ICC) of 95% (95%
confidence interval, 0.91 to 0.97) and 96% (95% confi-
dence interval, 0.92 to 0.97), respectively.
Hypertension was defined according to the Seventh
Report of the Joint National Committee [18]. The diagnoses
of impaired fasting glucose, impaired glucose tolerance, and
DM were based on the American Diabetes Association
2010 criteria [19]. The diagnosis of cardiovascular disease
was based on self-reports and confirmed using hospital
medical records.
Statistical analyses
The data were expressed as the means ± SD(SE), frequen-
cies or medians with 25th and 75th percentiles. Skewed
variables were logarithmically transformed to improve
normality prior to analysis. To evaluate the relationship
between each parameter and the 25(OH)D, the subjects
were stratified according to the 25(OH)D quartiles. The
ranges of 25(OH)D in the quartiles were 12.4-30.7,
30.8 -40.5, 40.6-53.0 and 53.2-153.0 nmol/L. Analysis
of covariance and logistic regression, with adjustments
for CVD risk factors, liver enzymes and the GFR wereconducted to compare means and proportions, respect-
ively, across the 25(OH)D quartiles. We used a general
linear model analyses and complete the homogeneity tests,
in which the outcome is the CIMT value of comparison
among 25(OH)D quartiles. We test the null hypothesis
that the error variance of the dependent variable is equal
across groups and get the result that p = 0.366. Regression
coefficients and odds ratios (ORs) were calculated for
a 1-unit increase in 25(OH)D. SPSS 16.0 for Windows
(SPSS 16.0 Inc Chicago, IL, USA)) was used to perform
the statistical analyses. All statistical tests were two tailed,
and p-values less than 0.05 were considered significant.
Results
Characteristics of the subjects according to the 25(OH)D
quartiles
A total of 671 postmenopausal women were evaluated.
The mean value of CIMT was 0.703 ± 0.123 mm. The
prevalence of carotid plaques was 15.4%. The mean
value of 25(OH)D was 43.6 ± 9.2 nmol/L. A total of 1.5%
of the subjects was current smokers. Table 1 shows the
clinical and biochemical parameters according to the
quartiles groups for the 25(OH)D. When the traditional
CVD risk factors were examined, WHR, DBP, PPG and
PTH were significantly associated with the 25(OH)D
quartiles. Other parameters were not significantly different
among the groups.
Association of the anthropometric and biochemical
parameters with serum 25(OH)D levels
Linear regression analysis showed an association between
25(OH)D and BMI, WHR, DBP, PPG and PTH (Table 2).
Multivariate linear stepwise regression analysis was
performed to evaluate the independent factors of 25
(OH)D. The analysis demonstrated that age (standardized
β = 0.082, p = 0.028), PTH (standardized β = -0.334,
p < 0.001), BMI (standardized β = -0.141, p = 0.001) and
PPG (standardized β= -0.053, p = 0.003) were independently
associated with serum 25(OH)D.
Association between carotid atherosclerosis and 25(OH)D
Table 3 presents the CIMT of the subjects according
to 25(OH)D quartile groups. Compared with the sub-
jects in the first, second and third 25(OH)D quartiles,
those in the fourth quartile had significantly thinner
CIMTs (0.684 ± 0.009 mm vs 0.719 ± 0.009 mm, 0.708 ±
0.009 mm and 0.709 ± 0.009 mm, respectively). After
adjusting for conventional CVD risk factors, liver enzymes
and the GFR, the subjects with 25(OH)D in the fourth
quartile still had lower CIMT than those in the first,
second and third quartiles (p = 0.039).
Compared with the subjects in the first, second and
third 25(OH)D quartiles, those in the fourth quartile had
significantly lower prevalence of carotid plaque (10.8%
Table 1 Characteristics of the subjects according to quartiles groups for 25(OH)D in subjects









25(OH) D range (nmol/L) 12.4-153.0 12.4-30.7 30.8 -40.5 40.6-53.0 53.2-153.0
Age (ys) 58.8(7.5) 57.9(7.4) 59.5(7.5)a 58.9(7.0) 59.0(8.0) 0.255
BMI (kg/m2) 22.8(2.9) 22.9(2.9) 22.8(2.8) 23.1(3.1) 22.4(2.8)c 0.238
WHR 0.853(0.063) 0.846(0.052) 0.855(0.061) 0.847 (0.061) 0.863(0.074)a,c 0.042
Current smoker, n (%) 10(1.5%) 4(2.4%) 3(1.8%) 1(0.6%) 2(1.2%) 0.572
SBP (mmHg) 120.0(11.1) 119.7(11.8) 120.8(11.1) 120.8(10.3) 118.7(11.1) 0.253
DBP (mmHg) 70.4(7.5) 71.2(7.6) 70.0(7.2) 71.3(7.3) 69.1(7.8)a,c 0.023
ALT (U/L) 16.9(9.5) 15.6(7.6) 16.4(7.2) 17.6(7.1) 17.8(7.5)a 0.107
AST (U/L) 21.1(6.1) 20.5(6.9) 20.7(5.5) 21.4(5.5) 21.7(6.5) 0.246
TC (mmol/L) 5.2(0.8) 5.2(0.8) 5.3(0.9) 5.4(0.9) 5.2(0.7)c 0.130
LDL-c (mmol/L) 3.0(0.7) 3.0(0.8) 3.0(0.7) 3.1(0.8) 2.9(0.7)c 0.096
HDL-c (mmol/L) 1.6(0.4) 1.6(0.4) 1.6(0.4) 1.6(0.4) 1.6(0.4) 0.605
TG (mmol/L) 1.4(0.7) 1.3(0.6) 1.3(0.6) 1.4(0.8) 1.4(0.7) 0.467
FBG (mmol/L) 4.9(0.3) 4.9(0.3) 4.9(0.4) 4.9(0.3) 4.9(0.3) 0.516
PPG (mmol/L) 5.7(1.1) 5.9(1.1) 5.5(1.0)a 5.4(1.0)a 5.4(0.9)a <0.001
PTH (pg/mL) 42.2(15.1) 48.6(16.3) 42.9(13.6)a 41.4(14.5)a 35.7(12.9)a,b,c <0.001
HOMA-IR 1.4(1.0-1.9) 1.3(1.0-2.0) 1.5(1.1-2.0) 1.5(1.0-2.0) 1.4(1.0-1.8) 0.425
HOMA-B % 97.4(72.7-128.6) 92.1(71.4-127.8) 98.6(75.6-131.0)a 102.1(70.8-134.7) 97.5(73.4-122.9) 0.1
GFR (ml/min per 1.73 m2) 96.9(18.9) 98.3(19.0) 96.2(19.2) 97.4(19.8) 96.0(17.6) 0.647
Data are mean (SD) or percentage of subjects or median (interquartile range).
BMI: body mass index, WHR: waist-hip-ratio, FBG: Fasting blood glucose, PPG: OGTT 2 h blood glucose, PTH: parathyroid hormone, SBP: systolic blood pressure,
DBP: diastolic blood pressure, ALT: alanine transaminase, AST: aspartate transaminase, TC: Total cholesterol, TG: triglyceride, HDL-C: high density lipoprotein
cholesterol, LDL-C: low density lipoprotein cholesterol, HOMA-IR: homeostasis model assessment index for insulin resistance, HOMA-B: homeostasis model assessment
index for beta cell function, GFR: glomerular filtration rate.
a Analysis of variance with LSD post-hoc test or Chi-square statistical analysis: P < 0.05 versus 1st quartile.
b Analysis of variance with LSD post-hoc test or Chi-square statistical analysis: P < 0.05 versus 2nd quartile.
c Analysis of variance with LSD post-hoc test or Chi-square statistical analysis: P < 0.05 versus 3rd quartile.
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for conventional CVD risk factors, liver enzymes and
the GFR, the subjects with 25(OH)D in the fourth
quartile had 0.421-fold decreased risks for carotid plaques
relative to those in the lowest quartile (95% confidence
interval 0.209 to 0.848) (Figure 1).
Discussion
Our study showed that serum 25(OH)D was independently
associated with carotid atherosclerosis in normotensive
and euglycemic Chinese postmenopausal women. The
CIMT and the prevalence of carotid plaques significantly
decreased with increasing serum 25(OH)D levels after
adjusting for conventional CVD risk factors, PTH, liver
enzymes and renal function in the subjects.
Serum 25(OH)D has recently become an interesting
topic in cardiovascular researches [1-6]. Although a
number of studies have demonstrated that 25(OH)D is
associated with the development of cardiovascular events,
it is still conflicting whether there is an independent
association between 25(OH)D and atherosclerotic CVD.
The participants in the Framingham Offspring Study [4]had 40% patients with hypertension and 8% diabetic
patients. European studies [5] were performed in diabetic
adults. The studies eligible for inclusion in the meta-
analysis by Wang [6], the study by Deleskog A [7], Blondon
M [8], Melamed [10] and the Korean National Health
and Nutrition Examination Survey [9] enrolled study
populations with different proportions of hypertension
or diabetes. As noted, recent studies have demonstrated
that there was a close association between 25(OH)D and
cardiovascular risk factors, such as hyperglycemia and
hypertension [11]. Studies suggest vitamin D deficiency
may be a contributor to the development of CVD poten-
tially through associations with diabetes or hypertension
[20]. In line with previous studies [11], serum 25(OH)D
concentrations were inversely associated with blood
pressure and blood glucose in the present study. Therefore,
the relationship between carotid atherosclerosis and serum
25(OH)D would be affected by the chronic effects of
increased blood glucose levels and blood pressure. The
impact of residual confounding factors would remain
after adjusting for hyperglycemia and hypertension in
previous studies. To eliminate the confounding effects
Table 2 Association of the anthropometric and biochemical parameters with serum 25(OH)D levels in postmenopausal
women
β (95% CI) Standardized β P
Age (per 1y) 0.154(-0.029-0.338) 0.064 0.1
BMI (per 1 units) -0.593(-1.063- -0.123) -0.095 0.013
WHR 25.129(3.130-47.128) 0.086 0.025
Current smoking -5.456(-16.840-5.928) -0.036 0.347
SBP (per 1 mmHg) -0.104(-0.229-0.020) -0.064 0.1
DBP (per 1 mmHg) -0.272(-0.455- -0.09) -0.112 0.004
ALT (1U/L) 0.130(-0.014-0.275) 0.068 0.077
AST (1U/L) 0.161(-0.064-0.386) 0.054 0.161
TC (1 mmol/L) -0.679(-2.323-0.965) -0.031 0.418
LDL-C (1 mmol/L) -1.199(-3.044-0.646) -0.049 0.202
HDL-C (1 mmol/L) -1.489(-5.121-2.143) -0.031 0.421
TG (1 mmol/L) -1.838(-2.788-0.111) -0.071 0.065
FBG (1 mmol/L) -2.853(-6.953-1.247) -0.053 0.172
PPG (1 mmol/L) -2.569(-3.862- -1.275) -0.149 0.001
PTH (1 pg/mL) -0.408(-0.494- -0.322) -0.338 <0.001
logHOMA-IR -4.853(-11.222-1.516) -0.058 0.135
logHOMA-B % 1.779(-0.079-3.480) 0.025 0.125
GFR (1 ml/min per 1.73 m2) -0.052(-0.125-0.021) -0.054 0.161
BMI: body mass index, WHR: waist-hip-ratio, FBG: Fasting blood glucose, PPG: OGTT 2 h blood glucose, PTH: parathyroid hormone, SBP: systolic blood pressure,
DBP: diastolic blood pressure, ALT: alanine transaminase, AST: aspartate transaminase, TC: Total cholesterol, TG: triglyceride, HDL-C: high density lipoprotein
cholesterol, LDL-C: low density lipoprotein cholesterol, HOMA-IR: homeostasis model assessment index for insulin resistance, HOMA-B: homeostasis model
assessment index for beta cell function, GFR: glomerular filtration rate.
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between carotid atherosclerosis and serum 25(OH)D, we
explored the relationship in the subjects with normal
blood pressure and normal glucose tolerance. Thus, the
association between 25(OH)D and carotid atherosclerosis
was not confounded by hyperglycemia and hypertension.
In the present study there was an independent association
between 25(OH)D and CIMT after adjusting for established
cardiovascular risk factors. As we known, CIMT may be
affected both by atherosclerosis and wall hypertrophy, weTable 3 CIMT in the subjects according to quartile groups for
Quartile groups for 25(OH) D in the subjects
1st quartile 2nd quartile
Unadjusted
CIMT (mm) 0.719(0.009) 0.708(0.009)
Model I
CIMT (mm) 0.712(0.009) 0.704(0.009)
Data are mean (SE).
a Analysis of variance with LSD (least significant difference) post-hoc test: P < 0.05 v
b Analysis of variance with LSD post-hoc test: P < 0.05 versus 2nd quartile.
c Analysis of variance with LSD post-hoc test: P < 0.05 versus 3rd quartile.
Model I: adjusting for age, FBG (fasting blood glucose), PPG (postprandial blood glu
ratio), current smoking, SBP (systolic blood pressure), DBP (diastolic blood pressure)
(high-density lipoprotein cholesterol), LDL-C (low-density lipoprotein cholesterol), lo
logHOMA-%B (homeostasis model assessment index for beta cell function) and GFR
cIMT: carotid intima-media thickness, 25 (OH) D: 25-hydroxyvitamin D.also assessed the association between 25(OH)D and
carotid plaque, which may be more representative of
atherosclerosis than CIMT and more informative for
predicting cardiovascular risk [21]. We demonstrated
a negative and independent relationship between 25
(OH)D and carotid plaque, independently from the
traditional risk factors. In contrast, Deleskog A et al [7]
reported that there were no independent relationships
between 25(OH)D and the baseline and progression
measures of carotid IMT in 3430 middle-aged and elderly25(OH)D in the subjects




cose), PTH(parathyroid hormone), BMI (body mass index), WHR (waist-to-hip
, ALT(alanine transaminase), AST(aspartate transaminase),TG (triglyceride), HDL-C
gHOMA-IR (homeostasis model assessment index for insulin resistance),
(glomerular filtration rate).
Figure 1 ORs of carotid plaque in the subjects across the 25(OH)D
quartile. ORs of carotid plaque in the subjects according to 25(OH)D
quartile groups after adjusting for age, BMI, WHR, FBG, PPG, SBP, DBP,
TG, HDL-C, LDL-C, smoking, ALT, AST, PTH, logHOMA-IR, logHOMA-B%
and the GFR, respectively. * Analysis of variance with logistic regression
analysis: P < 0.05 versus 1st quartile ORs and 95% CI are shown.
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CVD. Similarly, Blondon M et al [8] evaluated the associa-
tions of 25(OH)D with CIMT and carotid plaques among
3251 participants free of cardiovascular disease in the
Multi-Ethnic Study of Atherosclerosis and observed
consistent null results for both cross-sectional associations
and longitudinal associations evaluating change in IMT
and incident plaque during 10 years of follow-up. Several
explanations could be involved in the above different
results. First, the BMI, blood pressure, blood glucose
and lipid profile of the subjects in our study were
relatively improved in comparison with those in the
above studies. In addition, our subjects had a lower
proportion of smoking participants. Thus, the association
between 25(OH)D and CVD in subjects with higher
cardiovascular risk may be weakened for the greater
contribution of traditional atherosclerotic risks to
CVD in the studies of Deleskog A [7] and Blondon
M [8]. Second, there may be sex-related differences in
the association between 25(OH)D and CVD. These
sex-related differences might depend on background
data. It is known that the life-long risk for CVD is higher
for men than women [22]. Third, it is necessary to take
ethnic differences into account.
69.9% of subjects have 25(OH)D levels below 50 nmol/L.
Similarly, another study in China evaluated vitamin D sta-
tus of healthy adults living in Guiyang (latitude 26.5° north).
The study showed that the average serum 25(OH)D level of
20.4 ng/mL(51 nmol/L) and serum 25(OH)D was below
50 nmol/L in 52.3% [23]. Lu L et al [24] measured plasma
25(OH)D was in a cross-sectional sample of 1,443 men and
1,819 women aged 50-70 years from Beijing (latitude
40° north) and Shanghai (latitude 31° north). The median
value of plasma 25(OH)D was 35.6 nmol/l in Beijing and47.6 nmol/l in Shanghai, and the percentages of vitamin D
deficiency, insufficiency, and sufficiency were 69.2, 24.4,
and 6.4%, respectively. Indeed, poor vitamin D status in
middle and older Chinese individuals was also reported
previously in two small bone related studies conducted in
Beijing [25] and Shenyang [26]. The above data suggested
that vitamin D deficiency was common in middle-aged
and elderly Chinese individuals. Another explanation is
the exclusion criteria of the intake of the vitamin D
supplements in our study. Additionally, unlike in the
United States and other western countries, a racial/ethnic
difference may be exist in the levels of 25(OH)D concen-
trations. Although little is known regarding to the high
prevalence of vitamin D deficiency in our population, the
criteria of vitamin D deficiency in Chinese may differ from
that in the western population.
The mechanisms responsible for the independent
relationship between 25(OH)D and atherosclerosis have
not been well elucidated. In our study, 25(OH)D was
negatively associated with BMI, DBP and PPG. These
findings were also supported by other studies [27-29].
Therefore, the beneficial effects of 25(OH)D on atheroscler-
osis might be attributed to its ability to improve the glucose
metabolism and blood pressure control. On the other hand,
in the present study, we demonstrated an inversely and
independent association between 25(OH)D and carotid
atherosclerosis after adjustment for established CVD risk
factors, PTH, liver and renal function in postmenopausal
women with normal blood pressure and normal glucose
tolerance. If 25(OH)D and the other risk factors share a
common causal pathway, adjusting for these risk factors
may attenuate the relationship between 25(OH)D and
carotid atherosclerosis. However, 25(OH)D remained a
relatively strong predictor after full adjustment in our
study, suggesting that there was an independent additive
component in the relationship between 25(OH)D and
CVD. Thus, other atherogenic mechanisms could con-
ceivably be involved. Because many cell types involved in
cardiovascular function like cardiomyocytes, endothelial
cells, or vascular smooth muscle cells express vitamin D
receptors, a direct influence of vitamin D on the car-
diovascular system can be assumed [30]. There are
several mechanisms proposed to explain the inverse
relationship between vitamin D and CVD. First, activated
vitamin D is an inhibitor of the renin-angiotensin system
[31]. Vitamin D deficiency predisposes to up-regulation
of the renin–angiotensin–aldosterone system and
hypertrophy of the vascular smooth muscle cells [20,32].
Second, Vitamin D has effects that may favorably influence
cardiovascular system through strengthen in insulin
secretion and insulin sensitivity [33], down-regulate
coagulation through the up-regulation of thrombomodu-
lin [34], down-regulate vascular calcification [35-37]
and modulation of inflammatory processes [38]. Third,
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secondary hyperparathyroidism, which in turn may
mediate many of the detrimental CV effects including
increasing systemic inflammation, as indicated by increased
levels of C-reactive protein, homocysteine, and interleukin-
10 [32]. Fourth, vitamin D may play a pivotal role in cardiac
function. Cardiac muscle cells possess a vitamin D receptor
and a 1,25-dihydroxyvitaminD–dependent calcium-binding
protein. Vitamin D has effects on extra- cellular matrix
remodeling, myocardial cell hypertrophy, and proliferation
[20,39]. Vitamin D deficiency predisposes to lead to hyper-
trophy of the left ventricle. Fifth, activated vitamin D may
also retard atherosclerosis by inhibiting macrophage
cholesterol uptake and foam cell formation [40].
Our results suggest that 25(OH)D is a marker or risk
factor for atherosclerosis. 25(OH)D could be adopted as
an additional marker of the detection of CVD and the
implementation of interventions. An early evaluation
of the 25(OH)D would be advantageous for the early
detection of CVD, and individuals with decreased 25
(OH)D might benefit from more aggressive lifestyle
modifications and food-based strategies.
We recognize several limitations of this study: it is cross-
sectional, and the 25(OH)D was assessed based on a single
morning fasting blood sample. We also acknowledge that
in this analysis we do not have data on hours of sunlight
per day, albumin and vitamin D binding protein. The
cross-sectional nature of this study limits our ability to
determine causality. The potential confounding factors
remain, particularly in the absence of data for physical activ-
ity and socio-economic status. However, the temporal rela-
tionship between the 25(OH)D and carotid atherosclerosis
has been well established. Our participants were postmeno-
pausal women, and therefore, the results cannot be applied
to younger subjects. Hence, the association between 25
(OH)D and carotid atherosclerosis should be confirmed
using a larger sample and in prospective studies.
Conclusions
In conclusion, we demonstrated that 25(OH)D has a
negatively correlation with carotid atherosclerosis even
after adjusting for conventional CVD risk factors, PTH,
liver and renal function in postmenopausal women with
normal blood glucose levels and normal blood pressure.
Our findings suggest that individuals with decreased 25
(OH)D require aggressive management of CVD risk
factors. Should causality be affirmed by ongoing and
future studies, there are food-based strategies for enhanced
vitamin D status in the population which could ultimately
lower risk of CVD.
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